Page last updated: 2024-12-08

phrenosin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

phrenosin: galactoside from brain substance; yields galactose, sphingosine, phrenosinic acid on hydrolysis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-(beta-D-galactosyl)-N-[(2R)-2-hydroxylignoceroyl]sphingosine : A D-galactosyl-N-acylsphingosine in which the ceramide N-acyl group is specified as (R)-2-hydroxylignoceroyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID71768128
CHEBI ID75966
MeSH IDM0063545

Synonyms (15)

Synonym
phrenosin
CHEBI:75966
(2r)-n-[(2s,3r,4e)-1-(beta-d-galactopyranosyloxy)-3-hydroxyoctadec-4-en-2-yl]-2-hydroxytetracosanamide
2-hydroxytetracosanoylgalactosylceramide
1-(beta-d-galactosyl)-n-[(2r)-2-hydroxylignoceroyl]sphingosine
1-(d-galactosyl)-n-(2r)-2-hydroxy-tetracosanoylsphingosine
2-oh-24:0-galc
unii-xrv46r3bsq
tetracosanamide, n-((1s,2r,3e)-1-((beta-d-galactopyranosyloxy)methyl)-2-hydroxy-3-heptadecen-1-yl)-2-hydroxy-, (2r)-
tetracosanamide, n-((1s,2r,3e)-1-((.beta.-d-galactopyranosyloxy)methyl)-2-hydroxy-3-heptadecen-1-yl)-2-hydroxy-, (2r)-
phrenosine (ox brain)
586-02-7
phrenosin [mi]
XRV46R3BSQ ,
Q27145663
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acyl-beta-D-galactosylsphingosineAn N-acyl-D-galactosylsphingosine in which the anomeric configuration of the galactosyl residue is beta; sphingosine substituted at the O-1 position by a beta-D-galactosyl group and at the N-2 position by an acyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]